Opportunity ID: 293642

General Information

Document Type: Grants Notice
Funding Opportunity Number: W81XWH-17-BCRP-BREAKTHROUGH-FELLOWSHIP
Funding Opportunity Title: DoD BCRP Breakthrough Fellowship
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Grant
Category of Funding Activity: Science and Technology and other Research and Development
Category Explanation:
Expected Number of Awards: 11
Assistance Listings: 12.420 — Military Medical Research and Development
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: May 05, 2017
Last Updated Date:
Original Closing Date for Applications: Jun 15, 2017
Current Closing Date for Applications: Jun 15, 2017
Archive Date: Jul 15, 2017
Estimated Total Program Funding: $5,300,000
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility”
Additional Information on Eligibility:

Additional Information

Agency Name: Dept. of the Army — USAMRAA
Description:

The Breakthrough Fellowship Award supports recent doctoral or medical graduates in pursuit of
innovative, high-impact breast cancer research during their postdoctoral fellowship and allows them to obtain the necessary experience for an independent career at the forefront of breast cancer research. Those individuals should be exceptionally talented researchers who have demonstrated that they are the “best and brightest” of their peers. Applicants for this award must exhibit a strong desire to pursue a career in breast cancer research, with clear evidence for a researcher development plan that will lead to a successful independent career in breast cancer.
Applicants must also demonstrate that the proposed research has high potential to lead to or make breakthroughs in breast cancer.

The critical components of this award mechanism are:

Impact: Research supported by the Breakthrough Fellowship Award will have the potential for
a major impact and accelerate progress toward ending breast cancer. The impact may be near- term or long-term, but must be significant and move beyond an incremental advancement.
Applications must articulate the pathway to making a clinical impact for individuals with, or at risk for, breast cancer, even if clinical impact is not an immediate outcome.

Principal Investigator (PI): Under this award mechanism, the postdoctoral fellow is
considered the PI and, as such, should write the project narrative, researcher development plan, and other application components with appropriate guidance from the mentor. While the PI is not required to have previous experience in breast cancer research, the proposed project and researcher development plan must focus on breast cancer. Applications must emphasize the PI’s high potential for success in becoming an independent breast cancer researcher based on his/her qualifications, achievements (including first-author publications), and letters of recommendation.

Mentor: The mentor (or co-mentor, if applicable) must possess the appropriate expertise and experience in breast cancer, to include recent publications and active peer reviewed breast cancer funding, and clearly demonstrate a commitment to guiding the PI’s research and development as a researcher. If the mentor is not an experienced breast cancer researcher, then formal co- mentorship by an established breast cancer researcher is required. The application must include information about the mentor’s experience in conducting innovative research and how he/she intends to support the PI’s endeavors in breast cancer. Mentorship by an investigator without an
established record of mentoring pre- and/or postdoctoral trainees may be offset by the overall
strength of the researcher development plan.

Researcher Development Plan: Applications must provide details on the suitability of the PI’s research project and overall researcher development plan for attaining the goals of this award mechanism. The research project should be based on a sound scientific rationale and/or a thorough review of the literature. Preliminary data are allowed, but not required. Applications must elaborate on the qualities of the research environment in which the candidate will work, provide details on the individualized breast cancer-focused researcher development plan, and describe how it will facilitate the PI’s career development as an independent, innovative breast cancer researcher. A multidisciplinary research approach to breast cancer is highly encouraged, but not required; however, if there are multidisciplinary aspects, they should be clearly outlined in the application.

Research involving human subjects and human anatomical substances is permitted; however,
clinical trials are not allowed under this Program Announcement/Funding Opportunity.

Link to Additional Information:
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

CDMRP Help Desk

Phone: 301-682-5507

Email: help@eBRAP.org
Email:help@eBRAP.org

Version History

Version Modification Description Updated Date

Folder 293642 Full Announcement-FY17 BCRP Breakthrough Fellow -> BCRP_FY17_BFA_Eligibility Statement_GG.PDF

Folder 293642 Full Announcement-FY17 BCRP Breakthrough Fellow -> BCRP_FY17_BFA_Academic Statement_GG.PDF

Folder 293642 Full Announcement-FY17 BCRP Breakthrough Fellow -> BCRP_FY17_BFA_PA_GG.PDF

Packages

Agency Contact Information: CDMRP Help Desk
Phone: 301-682-5507
Email: help@eBRAP.org
Email: help@eBRAP.org
Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
12.420 PKG00232347 May 05, 2017 Jun 15, 2017 View

Package 1

Mandatory forms

293642 RR_SF424_2_0-2.0.pdf

293642 RR_Budget_1_4-1.4.pdf

293642 RR_KeyPersonExpanded_2_0-2.0.pdf

293642 PerformanceSite_2_0-2.0.pdf

293642 AttachmentForm_1_2-1.2.pdf

Optional forms

293642 RR_SubawardBudget30_1_4-1.4.pdf

2025-07-13T08:58:28-05:00

Share This Post, Choose Your Platform!

About the Author: